- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04506151
Ottimizzazione del sonno per migliorare il controllo glicemico negli adulti con diabete di tipo 1 (SOPT)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- University of Illinois Chicago
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Descrizione
Criterio di inclusione:
- adulti di età compresa tra 18 e 65 anni
- diagnosi clinica di diabete di tipo 1 minimo di un anno
- variabilità abituale del sonno segnalata (1 ora/settimana o più) o durata del sonno inferiore a 6,5 ore/notte durante i giorni lavorativi o feriali (confermato con actigraphy sleep watch)
- il desiderio di migliorare il sonno
- possedere uno smartphone
Criteri di esclusione:
- sintomi di insonnia
- ad alto rischio di apnea ostruttiva del sonno
- grave episodio di ipoglicemia negli ultimi 6 mesi (ad es. perdita di conoscenza)
- A1C maggiore del 10%
- turni a rotazione o turni notturni
- uso di sonniferi/aiutanti
- compromissione renale (velocità di filtrazione glomerulare stimata < 45 ml/min)
- significative morbilità mediche attuali (come insufficienza cardiaca, cirrosi, broncopneumopatia cronica ostruttiva che richiede ossigeno, trattamento attivo per il cancro, depressione, storia di ictus con deficit neurologici
- allattamento al seno, gravidanza o pianificazione della gravidanza
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Sleep-Opt
Intervento di 12 settimane che include automonitoraggio, definizione degli obiettivi, miglioramento motivazionale.
|
Intervento comportamentale di 12 settimane
|
|
Comparatore attivo: Vita sana
Intervento di 12 settimane che comprende contatto telefonico settimanale, contenuti didattici uguali nel tempo e attenzione al gruppo di intervento.
|
Vita sana
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Sleep Variability Week 6
Lasso di tempo: Week 6
|
Standard deviation total sleep time for one week
|
Week 6
|
|
Sleep Variability Week 12
Lasso di tempo: Week 12
|
Standard deviation total sleep time for one week
|
Week 12
|
|
Sleep Variability Week 24
Lasso di tempo: Week 24
|
Standard deviation total sleep time for one week
|
Week 24
|
|
Sleep Duration Week 6
Lasso di tempo: Weeks 6
|
total sleep time minutes
|
Weeks 6
|
|
Sleep Duration Week 12
Lasso di tempo: Week 12
|
total sleep time in minutes
|
Week 12
|
|
Sleep Duration Week 24
Lasso di tempo: Week 24
|
total sleep time in minutes
|
Week 24
|
|
HbA1C Week 6
Lasso di tempo: Week 6
|
Hemoglobin A1C week 6, %
|
Week 6
|
|
HbA1C Week 12
Lasso di tempo: Week 12
|
HbA1c blood test
|
Week 12
|
|
HbA1C Week 24
Lasso di tempo: Week 24
|
HbA1c blood test
|
Week 24
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Diabetes Distress Week 6
Lasso di tempo: Week 6
|
Type 1 Diabetes Distress Scale measures diabetes distress.
Item mean scores calculated (sum of scores/number of items) ranges from 1-6 Higher scores indicated greater distress Unit of measure = units on a scale
|
Week 6
|
|
Diabetes Distress Week 12
Lasso di tempo: Week 12
|
Type 1 Diabetes Distress Scale measures diabetes distress.
Item mean scores calculated (sum of scores/number of items) ranges from 1-6 Higher scores indicated greater distress Unit of measure = units on a scale
|
Week 12
|
|
Diabetes Distress Week 24
Lasso di tempo: Week 24
|
Type 1 Diabetes Distress Scale measures diabetes distress.
Item mean scores calculated (sum of scores/number of items) ranges from 1-6 Higher scores indicated greater distress Unit of measure = units on a scale
|
Week 24
|
|
Self-management Behavior Week 6
Lasso di tempo: Week 6
|
Diabetes Self Management Questionnaire-R (DSMQ-R) measures diabetes self-management Item mean scores calculated (sum of scores/maximum possible sum of items * 10).
Ranges from 0-10.
Higher numbers indicate better self-management behavior Unit of measure = units on a scale
|
Week 6
|
|
Self Management Behavior Week 12
Lasso di tempo: Week 12
|
Diabetes Self Management Questionnaire-R (DSMQ-R) measures diabetes self-management Item mean scores calculated (sum of scores/maximum possible sum of items * 10).
Scores ranges from 0-10.
Higher numbers indicate better self-management behavior Unit of measure = units on a scale
|
Week 12
|
|
Self Management Behavior Week 24
Lasso di tempo: Week 24
|
Diabetes Self Management Questionnaire-R (DSMQ-R) measures diabetes self-management Item mean scores calculated (sum of scores/maximum possible sum of items * 10).
Ranges from 0-10.
Higher numbers indicate better self-management behavior Unit of measure = units on a scale
|
Week 24
|
|
Quality of Life Week 6
Lasso di tempo: Week 6
|
Diabetes Quality of Life scale measures quality of life Total quality of life score calculated as follows: (Raw total score - lowest possible score)/raw score range * 100. Scores range from 0-100. Scores are reverse coded so that higher numbers indicate better quality of life. Unit of measure = units on a scale |
Week 6
|
|
Quality of Life Week 12
Lasso di tempo: Week 12
|
Diabetes Quality of Life scale measures quality of life Total quality of life score calculated as follows: (Raw total score - lowest possible score)/raw score range * 100. Scores range from 0-100. Scores are reverse coded so that higher numbers indicate better quality of life. Unit of measure = units on a scale. |
Week 12
|
|
Quality of Life Week 24
Lasso di tempo: Week 24
|
Diabetes Quality of Life scale measures quality of life Total quality of life score calculated as follows: (Raw total score - lowest possible score)/raw score range * 100. Scores range from 0-100. Scores are reverse coded so that higher numbers indicate better quality of life. Unit of measure = units on a scale. |
Week 24
|
|
Fatigue Week 6
Lasso di tempo: Week 6
|
Patient Reported Outcomes Measure (PROMIS) fatigue scale score measures fatigue. The total score was converted to T-scores (with T-scores, 50 indicates the population mean with a standard deviation of 10). Mean T-scores were calculated. Higher scores reflect greater fatigue. |
Week 6
|
|
Fatigue Week 12
Lasso di tempo: Week 12
|
Patient Reported Outcomes Measure (PROMIS) fatigue scale score measures fatigue. The total score was converted to T-scores (with T-scores, 50 indicates the population mean with a standard deviation of 10). Mean T-scores were calculated. Higher scores reflect greater fatigue. |
Week 12
|
|
Fatigue Week 24
Lasso di tempo: Week 24
|
Patient Reported Outcomes Measure (PROMIS) fatigue scale score measures fatigue. The total score was converted to T-scores (with T-scores, 50 indicates the population mean with a standard deviation of 10). Mean T-scores were calculated. Higher scores reflect greater fatigue. |
Week 24
|
|
Mood Week 6
Lasso di tempo: Week 6
|
Center for Epidemiological Studies-Depression (CES-D) measures depressive mood.
Total summed score ranges from 0-60.
Higher scores indicate greater depressive mood.
Unit of measure = units on a scale.
|
Week 6
|
|
Mood Week 12
Lasso di tempo: Week 12
|
Center for Epidemiological Studies-Depression (CES-D) measures depressive mood.
Total summed score ranges from 0-60.
Higher scores indicate greater depressive mood.
Unit of measure = units on a scale.
|
Week 12
|
|
Mood Week 24
Lasso di tempo: Week 24
|
Center for Epidemiological Studies-Depression (CES-D) measures depressive mood.
Total summed score ranges from 0-60.
Higher scores indicate greater depressive mood.
Unit of measure = units on a scale.
|
Week 24
|
|
Subjective Sleep Quality Week 6
Lasso di tempo: Week 6
|
Pittsburgh Sleep Quality Index (PSQI) measures subjective sleep quality.
Total summed score ranges 0-21.
Higher score reflects poorer sleep quality.
Unit of measure = units on a scale.
|
Week 6
|
|
Subjective Sleep Quality Week 12
Lasso di tempo: Week 12
|
Pittsburgh Sleep Quality Index (PSQI) measures subjective sleep quality.
Total summed score ranges 0-21.
Higher score reflects poorer sleep quality.
Unit of measure = units on a scale.
|
Week 12
|
|
Subjective Sleep Quality Week 24
Lasso di tempo: Week 24
|
Pittsburgh Sleep Quality Index (PSQI) measures subjective sleep quality.
Total summed score ranges 0-21.
Higher score reflects poorer sleep quality.
Unit of measure = units on a scale.
|
Week 24
|
|
Glycemic Variability Week 6
Lasso di tempo: Week 6
|
Coefficient of variation (CV%), continuous glucose monitoring (CGM)-derived glucose standard deviation (SD) divided by the mean and multiplied by 100.
|
Week 6
|
|
Glycemic Variability Week 12
Lasso di tempo: Week 12
|
Coefficient of variation (CV%), continuous glucose monitoring (CGM)-derived glucose standard deviation (SD) divided by the mean and multiplied by 100.
|
Week 12
|
|
Glycemic Variability Week 24
Lasso di tempo: Week 24
|
Coefficient of variation (CV%), continuous glucose monitoring (CGM)-derived glucose standard deviation (SD) divided by the mean and multiplied by 100.
|
Week 24
|
|
Glucose Time-in-range Week 6
Lasso di tempo: Week 6
|
Percent of time continuous glucose monitoring (CGM)-derived glucose is between 70-180 mg/dL.
|
Week 6
|
|
Glucose Time-in-range Week 12
Lasso di tempo: Week 12
|
Percent of time continuous glucose monitoring (CGM)-derived glucose is between 70-180 mg/dL.
|
Week 12
|
|
Glucose Time-in-range Week 24
Lasso di tempo: Week 24
|
Percent of time continuous glucose monitoring (CGM)-derived glucose is between 70-180 mg/dL.
|
Week 24
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Tests of the Sleep Intervention Effect on A1C That is Due to the Change in Sleep Duration
Lasso di tempo: week 12
|
Mediation tests of the sleep intervention effect on A1C that is due to the change in sleep duration.
It is the product of parameter estimates testing the effect of the intervention on sleep duration and the mediating effect of the change in sleep duration on A1C.
Markov chain Monte Carlo (MCMC) models were used.
|
week 12
|
|
Mediation Tests of the Sleep Intervention Effect on A1C That is Due to the Change in Sleep Variability.
Lasso di tempo: Week 12
|
Results are not reported by treatment arm.
This analysis tests the sleep intervention effect on A1C that is mediated by the change in sleep variability.
The values reported are the product of parameter estimates testing the effect of the intervention on sleep variability and the effect of the change in sleep variability on A1C.
Markov chain Monte Carlo (MCMC) models were used.
|
Week 12
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Pamela Martyn-Nemeth, PhD, University of Illinois at Chicago
Pubblicazioni e link utili
Pubblicazioni generali
- Martyn-Nemeth P, Duffecy J, Quinn L, Reutrakul S, Steffen AD, Burke L, Clark Withington MH, Irsheed GA, Perez R, Park M, Saleh A, Mihailescu D, Baron KG. Sleep optimization to improve glycemic control in adults with type 1 diabetes: study protocol for a randomized controlled parallel intervention trial. Trials. 2022 Aug 19;23(1):686. doi: 10.1186/s13063-022-06565-6.
- Hong SJ, Pratuangtham S, Martyn-Nemeth P, Steffen AD, Park CG, Reutrakul S. Blue Light Exposure During Sleep in Type 1 Diabetes: Impacts on Glycemic Control and Psychosocial Health. J Sleep Res. 2026 Jun 5:e70380. doi: 10.1111/jsr.70380. Online ahead of print.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2020-0374
- 1R01DK121726 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .